CAS 722533-56-4

Elacestrant

Description:

Elacestrant, with the CAS number 722533-56-4, is a selective estrogen receptor degrader (SERD) that is primarily investigated for its potential in treating estrogen receptor-positive breast cancer. It functions by binding to the estrogen receptor, leading to its degradation and thereby inhibiting estrogen-driven tumor growth. Elacestrant is characterized by its ability to selectively target and modulate estrogen receptor activity, which distinguishes it from traditional anti-estrogens. The compound is typically administered orally and has been studied in clinical trials for its efficacy and safety profile in patients with advanced breast cancer. Its chemical structure includes specific functional groups that contribute to its activity and pharmacokinetics. As a SERD, Elacestrant represents a novel therapeutic approach, particularly for patients who have developed resistance to conventional endocrine therapies. Ongoing research continues to evaluate its role in combination therapies and its long-term effects on patient outcomes.

Synonyms:

• 2-Naphthalenol, 6-[2-[ethyl[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydro-, (6R)-

Elacestrant

CAS: 722533-56-4

Elacestrant (RAD1901) with IC50s of 48 and 870 nM for ERα and ERβ, respectively.Elacestrant  is an orally available selective estrogen receptor degrader .

Formula: C₃₀H₃₈N₂O₂

Purity: 98.31%

Color and Shape: Solid

Molecular weight: 458.63

Ref: TM-T13674

(6R)-6-[2-[Ethyl[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydro-2-naphthalenol

CAS: 722533-56-4

Formula: C₃₀H₃₈N₂O₂

Purity: 99.80%

Color and Shape: Solid

Molecular weight: 458.6349

Ref: IN-DA01EO6Z

Elacestrant

CAS: 722533-56-4

Elacestrant

Purity: ≥98%

Molecular weight: 458.63g/mol

Ref: 54-BUP04874

Elacestrant

Controlled Product

CAS: 722533-56-4

Elacestrant is a selective estrogen receptor degrader (SERD), which is a synthetic small-molecule compound specifically engineered to target and bind to estrogen receptors. Its primary mechanism of action involves the degradation and downregulation of these receptors, thereby impeding the proliferative signaling pathways that are driven by estrogen in hormone receptor-positive breast cancer cells.

Formula: C₃₀H₃₈N₂O₂

Purity: Min. 95%

Molecular weight: 458.6 g/mol

Ref: 3D-XDB53356